1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Solvotrin Therapeutics Ltd - Product Pipeline Review - 2014

Solvotrin Therapeutics Ltd - Product Pipeline Review - 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 18 pages

Solvotrin Therapeutics Ltd - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Solvotrin Therapeutics Ltd - Product Pipeline Review - 2014’, provides an overview of the Solvotrin Therapeutics Ltd’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Solvotrin Therapeutics Ltd’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Solvotrin Therapeutics Ltd including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Solvotrin Therapeutics Ltd’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Solvotrin Therapeutics Ltd’s pipeline products

Reasons to buy

- Evaluate Solvotrin Therapeutics Ltd’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Solvotrin Therapeutics Ltd in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Solvotrin Therapeutics Ltd’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Solvotrin Therapeutics Ltd and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Solvotrin Therapeutics Ltd
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Solvotrin Therapeutics Ltd and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Solvotrin Therapeutics Ltd - Product Pipeline Review - 2014
Table of Contents

Solvotrin Therapeutics Ltd Snapshot 4
Solvotrin Therapeutics Ltd Overview 4
Key Information 4
Key Facts 4
Solvotrin Therapeutics Ltd - Research and Development Overview 5
Key Therapeutic Areas 5
Solvotrin Therapeutics Ltd - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Solvotrin Therapeutics Ltd - Pipeline Products Glance 9
Solvotrin Therapeutics Ltd - Early Stage Pipeline Products 9
Preclinical Products/Combination Treatment Modalities 9
Solvotrin Therapeutics Ltd - Drug Profiles 10
ST-0701 10
Product Description 10
Mechanism of Action 10
RandD Progress 10
ST-0702 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
ST-0703 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
Solvotrin Therapeutics Ltd - Pipeline Analysis 13
Solvotrin Therapeutics Ltd - Pipeline Products by Target 13
Solvotrin Therapeutics Ltd - Pipeline Products by Molecule Type 14
Solvotrin Therapeutics Ltd - Pipeline Products by Mechanism of Action 15
Solvotrin Therapeutics Ltd - Locations And Subsidiaries 16
Head Office 16
Appendix 17
Methodology 17
Coverage 17
Secondary Research 17
Primary Research 17
Expert Panel Validation 17
Contact Us 18
Disclaimer 18

List of Tables

Solvotrin Therapeutics Ltd, Key Information 4
Solvotrin Therapeutics Ltd, Key Facts 4
Solvotrin Therapeutics Ltd - Pipeline by Indication, 2014 6
Solvotrin Therapeutics Ltd - Pipeline by Stage of Development, 2014 7
Solvotrin Therapeutics Ltd - Monotherapy Products in Pipeline, 2014 8
Solvotrin Therapeutics Ltd - Preclinical, 2014 9
Solvotrin Therapeutics Ltd - Pipeline by Target, 2014 13
Solvotrin Therapeutics Ltd - Pipeline by Molecule Type, 2014 14
Solvotrin Therapeutics Ltd - Pipeline Products by Mechanism of Action, 2014 15

List of Figures

Solvotrin Therapeutics Ltd - Pipeline by Top 10 Indication, 2014 6
Solvotrin Therapeutics Ltd - Pipeline by Top 10 Target, 2014 13
Solvotrin Therapeutics Ltd - Pipeline Products by Top 10 Mechanism of Action, 2014 15

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016 Summary Global Markets ...

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Pipeline Review, H2 2016

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.